BIOVECTRA signs service agreement with Acuitas Therapeutics for unique lipid nanoparticle (LNP) delivery system used in manufacturing mRNA-based therapies Post author: Post published:October 6, 2023 Post category:uncategorized BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service. You Might Also Like Breakthrough in chicken genomics offers hope against avian influenza April 10, 2025 UCLA research highlights delayed Huntington’s disease diagnosis for Black patients July 9, 2024 Understanding the connection between brain networks and cognitive deficits in psychotic disorders August 20, 2024
Understanding the connection between brain networks and cognitive deficits in psychotic disorders August 20, 2024